Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Phenylketonuria (PKU) is a rare genetic condition. If not treated, PKU can cause severe mental retardation. Women with PKU are advised to eat a special diet when pregnant to prevent mental retardation in their children. This study will evaluate the effects of that diet on the children of mothers with PKU.
| Condition | Intervention |
|---|---|
|
Phenylketonuria |
Behavioral: Restricted phenylalanine diet |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effects of Maternal Phenylketonuria (PKU) on Pregnancy Outcome |
| Estimated Enrollment: | 572 |
| Study Start Date: | May 1984 |
| Estimated Study Completion Date: | April 2000 |
PKU is an autosomal recessive trait caused by the absence of phenylalanine hydroxylase. Phenylalanine hydroxylase is an enzyme involved in the metabolism of phenylalanine (Phe). When phenylalanine hydroxylase is absent or defective, Phe levels rise and toxic Phe metabolites accumulate, causing central nervous system injury. PKU is a treatable disease. Affected individuals must adhere to a diet low in Phe during childhood. Women with PKU should also adhere to a low Phe diet before and during pregnancy to avoid fetal damage. The offspring of women with untreated maternal hyperphenylalaninemia (HPA) usually exhibit mental retardation, microcephaly, growth retardation, and other congenital anomalies. This study will examine the effect of a restricted Phe diet on reproductive outcome in women with maternal HPA.
Participants in this study will be women with HPA whose blood Phe values are persistently greater than 4 mg/dl. Those women with blood Phe values consistently greater than 8 mg/dl will be placed on a Phe restricted diet to maintain plasma Phe concentrations between 2 and 8 mg/dl. This level of control is practical and achievable. Due to a gradient of increasing Phe level from mother to fetus, levels in the latter would vary from 3.5 to 12 mg/dl; these levels are usually associated with normal outcomes. Women will be monitored throughout their pregnancy on obstetric, biochemical, and nutritional parameters. Women on the Phe restricted diet will be given enough Phe-limited protein, calories, vitamins, and minerals to maintain adequate nutritional status. Folate supplementation will be provided. If indicated clinically, tyrosine (Tyr) and supplemental trace metals will be prescribed.
A matching control sample of women and their offspring will be developed in collaboration with associated coordinating and collaborating centers. The offspring of both groups of mothers will be followed as long as the project permits. Those offspring born to mothers admitted to the project during the first 2 to 3 years of the study will be assessed on their intellectual ability and physical health, as well as academic achievement in school. Those admitted during the last 3 to 4 years of the study will be assessed on their intellectual ability and physical health, recognizing that limited data will be available for these offspring.
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
- Live in community setting
- Become pregnant or give birth during the term of the investigation
- Identified early in pregnancy
- Dietary therapy instituted prior to conception whenever possible
- Diagnosis of PKU based on results of Phe challenge, or clear diagnostic evidence in medical record
- Blood Phe > 4 mg/dl
- Intellectually able to understand and comply with the requirements of the Phe restricted diet, understand an informed consent, and adequately communicate with clinic personnel
- IQ > 70
Inclusion Criteria for Controls
- Heterozygous sisters to HPA women
- Matched control from maternity facility; pregnancy and offspring from a non-PKU female and a PKU male
Exclusion Criteria
- Women with evidence of pterin defect
Contacts and Locations| United States, California | |
| University of Southern California School of Medicine | |
| Los Angeles, California, United States, 90027 | |
| United States, Illinois | |
| University of Illinois at Chicago | |
| Chicago, Illinois, United States | |
| United States, Texas | |
| University of Texas Medical Branch at Galveston | |
| Galveston, Texas, United States | |
| Principal Investigator: | Richard Koch, M.D. | University of Southern California |
| Principal Investigator: | Reuben Matalon, M.D. | University of Illinois |
| Principal Investigator: | Bobbye M. Rouse, M.D. | University of Texas at Galveston |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00065299 History of Changes |
| Other Study ID Numbers: | NICHD-PKU, 1N01HD23148, 1N01HD23155, 1N01HD23156 |
| Study First Received: | July 21, 2003 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Federal Government |
Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
|
Hyperphenylalaninemia PKU Maternal PKU Pregnancy outcome |
Phenylalanine restricted diet Tyrosine supplementation Maternal hyperphenylalanemia during pregnancy |
Additional relevant MeSH terms:
|
Phenylketonurias Phenylketonuria, Maternal Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Amino Acid Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases Pregnancy Complications |
ClinicalTrials.gov processed this record on May 19, 2013